We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Adults infected with the Omicron variant are 29 percent less likely to enter the hospital than people infected with other COVID-19 strains, according to the first large-scale real-world clinical data. Read More
Final data from the phase 2/3 study of Pfizer’s novel oral “at home” COVID-19 treatment, Paxlovid, was so strong, the candidate could be well-positioned to knock molnupiravir — which is authorized in the UK although not yet in the U.S. — off its perch. Read More
The findings are in line with newly published data from the UK Health Security Agency, which showed reduced vaccine effectiveness against Omicron vs. the Delta variant. Read More
The Pfizer/BioNTech and Moderna COVID-19 vaccines are 25-40 times less effective against the new Omicron variant than the original strain and Delta variants, two new laboratory studies have found. Read More
In the U.S., an FDA advisory committee narrowly backed authorizing molnupiravir last week, but the agency has yet to approve the COVID-19 pill for emergency use. Read More
The WHO said the evidence was less certain for severe and critically ill COVID-19 patients and suggested trials continue for this subgroup to gather more data. Read More
Gilead Sciences has recalled two lots of its blockbuster COVID-19 antiviral Veklury (remdesivir) for possible contamination with glass particulates. Read More
The FDA has revised the Emergency Use Authorization (EUA) covering Eli Lilly’s COVID-19 antibody cocktail (bamlanivimab/etesevimab), enabling its use in children as young as babies with mild to moderate COVID-19 at high risk of progressing to severe disease. Read More
Several different COVID-19 booster shot combinations appear to improve protection against infection but the messenger RNA (mRNA)-based jabs from Pfizer and Moderna might be the most effective. Read More
RSS
